Recent advance in perampanel in treating special population with epilepsy
10.3760/cma.j.cn115354-20221124-00858
- VernacularTitle:吡仑帕奈治疗癫痫特殊人群的研究进展
- Author:
Jiaqin YI
1
;
Dan SUN
Author Information
1. 华中科技大学同济医院附属武汉儿童医院神经内科，武汉 430016
- Keywords:
Epilepsy;
Perampanel;
Child patient;
Female patient;
Elderly patient
- From:
Chinese Journal of Neuromedicine
2023;22(2):194-199
- CountryChina
- Language:Chinese
-
Abstract:
Perampanel, one of the third-generation antiseizure drugs, can non-competitively bind a-amino-3- hydroxyl-5-methyl-4-isoxazole-propionate receptor. It has been approved for both monotherapy and adjunctive treatment of patients≥4 years old with focal epilepsy (with or without secondary generalized seizures) in China. Researches on treatment of perampanel in special population such as children, the elderly and women have been constantly updated, but summaries on them are lacked recently. This review summarizes the latest clinical studies on the above-mentioned population, providing reasonable basis for clinicians.
